Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $1

Futu NewsDec 21, 2024 21:32 · Ratings

Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Cuts Target Price to $1

Futu NewsDec 21, 2024 02:31 · Ratings

Catalyst Watch: FOMC Meeting, Govt. Funding Drama, Earnings for Micron, Nike, and FedEx

Seeking AlphaDec 14, 2024 04:00

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BenzingaDec 12, 2024 05:06

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

WSJDec 12, 2024 02:29

Cellectar Biosciences Cut to Perform From Outperform by Oppenheimer

Dow JonesDec 12, 2024 01:57 · Ratings